ATH-1020 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Athira Pharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.

Summary

This trial tests a new drug called ATH-1020 in healthy young and elderly people to see if it is safe and how the body handles it. Researchers will also check if the drug can reach the brain.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.

This trial's timeline: 3 weeks for screening, Varies for treatment, and samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Secondary study objectives

Amount of IMP excreted unchanged in the urine (Ae)

Area under the plasma concentration time curve (AUC)

Half-life (t1/2)

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: ATH-1020Experimental Treatment1 Intervention

ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).

Group II: PlaceboPlacebo Group1 Intervention

Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ATH-1020

2022

Completed Phase 1

~40

Do I qualify?Apply below to find out